Forensic Genomics Market (2026-2036)

The growth of this market is mainly driven by the expansion of national DNA databases and the growing number of offender, arrestee, and crime scene profiles processed each year; government funding for crime laboratory capacity and DNA backlog reduction; the rapid adoption of investigative genetic genealogy to resolve violent crimes, cold cases, and unidentified human remains; and the increasing use of Rapid DNA systems in booking stations and, more recently, for crime scene samples. In addition, the adoption of next-generation sequencing (NGS) for forensic analysis of degraded and mixed samples, the growing use of probabilistic genotyping software, the expansion of disaster victim identification and missing persons programs, and cross-border DNA data exchange are further supporting the growth of this market.

The Forensic Genomics Market, also referred to as the forensic DNA analysis market, DNA forensics market, or forensic human identification market, comprises the kits and consumables, instruments, software, and services used to analyze human DNA for criminal investigation, DNA databasing, identification of missing persons and disaster victims, and kinship testing. The market includes sample collection and DNA extraction products; DNA quantification kits; short tandem repeat (STR) amplification kits, including autosomal, Y-chromosome, and X-chromosome STR kits; capillary electrophoresis genetic analyzers; Rapid DNA instruments and cartridges; forensic NGS panels and sequencers that analyze STRs, single nucleotide polymorphisms (SNPs), mitochondrial DNA, and ancestry and phenotype markers; whole-genome sequencing and dense SNP genotyping for investigative genetic genealogy; laboratory automation; probabilistic genotyping, analysis, and database software; and forensic DNA testing and genealogy services. The market ecosystem extends from manufacturers of forensic kits, instruments, and software to public crime laboratories, law enforcement agencies, medical examiners, private forensic laboratories, genetic genealogy service providers, and research institutions.

DNA analysis has become one of the most powerful tools in criminal justice. DNA profiles generated from crime scene evidence can be compared with profiles of suspects and searched against national databases to identify offenders, link crimes, and exonerate the innocent. According to the Federal Bureau of Investigation (FBI), the National DNA Index System (NDIS) holds more than 26.5 million offender DNA profiles and more than 1.48 million crime scene DNA profiles, the Combined DNA Index System (CODIS) has aided more than 776,000 investigations, more than 200 laboratories participate in NDIS, and CODIS software is used at 132 sites in 65 countries. The growth of these databases, driven by laws requiring DNA collection from convicted offenders and, in many jurisdictions, from arrestees, creates recurring demand for collection kits, STR kits, genetic analyzers, and laboratory capacity.

Public funding is central to the market, as most forensic DNA analysis is performed by government laboratories. In 2026, the U.S. Bureau of Justice Assistance (BJA) opened the FY 2026 DNA Capacity Enhancement for Backlog Reduction (CEBR) Competitive Grants Program, offering up to USD 4.9 million to increase the capacity of public crime laboratories to process DNA samples for entry into CODIS, including a dedicated category for implementing Rapid DNA in booking stations. Crime laboratories in many countries face backlogs of sexual assault kits and other casework, and governments fund equipment, automation, staff, and outsourcing to private laboratories to reduce turnaround times. The FBI Quality Assurance Standards and accreditation requirements govern the methods and products used by laboratories that contribute to CODIS.

Investigative genetic genealogy has transformed cold case investigation. Unlike traditional STR profiling, which can only identify an individual already in a database, genealogy-based methods use hundreds of thousands of SNPs, generated by whole-genome sequencing or dense SNP genotyping, to identify distant relatives in consumer genealogy databases and build family trees leading to an identification. Investigative genetic genealogy has helped resolve more than 1,600 cases in the U.S. and Canada, according to an ongoing tally reported by NBC News, and Othram, a Texas-based forensic genomics laboratory, states that its work has helped solve at least 600 cold cases; in April 2026, the Florida Attorney General announced a USD 600,000 partnership with Othram to address a backlog of more than 21,000 unsolved murder cases in the state. The proposed Carla Walker Act in the U.S. would provide USD 10 million in annual federal grants to help law enforcement pay for genetic genealogy services, reflecting growing policy support.

Rapid DNA is extending DNA analysis beyond the laboratory. Under the Rapid DNA Act of 2017, the FBI approved Rapid DNA systems, including the ANDE 6C Series G and the RapidHIT ID DNA Booking System, for use in law enforcement booking stations, allowing arrestee DNA profiles to be generated and searched in less than two hours. In July 2026, the FBI approved the Applied Biosystems RapidINTEL Plus Cartridge of Thermo Fisher Scientific, used with the RapidHIT ID System, for qualifying forensic crime scene samples, making it the first Rapid DNA workflow whose crime scene profiles are eligible for national CODIS searches after review by qualified laboratory personnel; in one example, Connecticut investigators generated an investigative lead in about 90 minutes for evidence that traditionally took about 90 days to process. These developments are expected to increase the speed of investigations and expand the use of Rapid DNA by law enforcement agencies.

The market includes life science companies such as Thermo Fisher Scientific, QIAGEN (which acquired Verogen, the forensic NGS company, in 2023), and Promega Corporation, which supply STR kits, genetic analyzers, NGS solutions, and automation; Rapid DNA specialists such as ANDE Corporation; forensic genomics and genealogy laboratories such as Othram and Parabon NanoLabs; and forensic DNA service providers such as Bode Technology and Eurofins Scientific. These companies compete on sensitivity with low-template and degraded samples, the ability to resolve mixtures, compatibility with national database standards, validation and accreditation support, throughput and turnaround time, and software.

At the same time, the market faces challenges, including privacy, ethical, and legal concerns about investigative genetic genealogy and the expansion of DNA databases, differences in national laws governing DNA collection and retention, the limited budgets and staffing of public crime laboratories, the complexity of interpreting mixed and low-level DNA profiles, and the need to validate new technologies such as NGS before they can be used in casework. As a result, companies that combine validated, database-compatible products, solutions for difficult samples, Rapid DNA and NGS capabilities, interpretation software, and strong support for laboratory accreditation are expected to capture the largest share of growth over the forecast period.